International Journal of Clinical Research

Objective To analyze the efficacy of alteplase in the treatment of acute cerebral infarction. Methods seventy-two patients with acute cerebral infarction, who were treated in our hospital during the study period from May to 20232021, were selected for the study, according to the difference of treatment methods, 36 patients with conventional therapy (non-thrombolytic therapy) were divided into control group and 36 patients with thrombolytic therapy of alteplase were divided into observation group, the NHISS neurological deficit scale (NDS) and adverse drug reactions (adrs) were compared between the two groups. Results before treatment, there was no significant difference in NHISS nerve defect score between the two groups (P > 0.05) . The NHISS scores of the patients were significantly decreased at 6H, 24h and 72h after treatment (p < 0.05) . On the side effects, the number of symptomatic cerebral hemorrhage, subcutaneous mucosal hemorrhage and oral hemorrhage in the observation group was significantly lower than that in the control group (p ﹥ 0.05) . Conclusion alteplase can improve the nerve damage of patients with acute cerebral infarction, reduce the prognosis of rehabilitation disorders, and the drug reaction is low, the treatment of safety is good.

Alteplase; Acute cerebral infarction; Thrombolysis; Clinical efficacy; Safety